fbpx

Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (Nasdaq:RCKT) (“Rocket”), a leading
U.S.-based multi-platform gene therapy company, today announces the
closing of its previously announced underwritten public offering of
5,175,000 shares of its common stock, which includes the full exercise
of the underwriters’ option to purchase 675,000 additional shares of its
common stock, at a public offering price of $17.50 per share. The gross
proceeds to Rocket from the offering are expected to be approximately
$90.6 million, before deducting the underwriting discounts and
commissions and other offering expenses.

Rocket intends to use the net proceeds from this offering to further
fund the development of its pipeline of gene therapies for rare
diseases, to accelerate the buildout of in-house manufacturing
capabilities, and for general corporate purposes.

SVB Leerink, Evercore ISI and William Blair acted as joint-bookrunning
managers for the offering. Oppenheimer & Co. acted as lead manager for
the offering.

The public offering was made by Rocket pursuant to an effective shelf
registration statement on Form S-3 that was previously filed with the
U.S. Securities and Exchange Commission (the “SEC”) and declared
effective by the SEC. A final prospectus supplement relating to and
describing the terms of this offering was filed with the SEC on April
17, 2019. Copies of the final prospectus supplement and the accompanying
prospectus relating to these securities may be obtained from SVB Leerink
LLC, Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email [email protected];
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd
Street, 36th Floor, New York, NY 10055, by telephone at (888) 474-0200,
or by email at [email protected];
and William Blair & Company, L.L.C., Attention: Prospectus Department,
150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800)
621-0687, or by email at [email protected].
You may also obtain these documents free of charge by visiting the SEC’s
website at www.sec.gov.

This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.

Forward-looking Statements

Various statements in this release concerning Rocket’s future
expectations, plans and prospects, including without limitation, the
anticipated use of the net proceeds of the offerings, may constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995
and other federal securities laws and are subject to substantial risks,
uncertainties and assumptions. You should not place reliance on these
forward-looking statements, which often include words such as
“anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“seek,” “should,” “suggest,” “target,” “will,” “will give,” “would,” or
similar terms, variations of such terms or the negative of those terms.
Although Rocket believes that the expectations reflected in the
forward-looking statements are reasonable, Rocket cannot guarantee such
outcomes. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including, without limitation, changes as a result of market
conditions or for other reasons, the risk that the offerings will not be
consummated, and the impact of general economic, industrial or political
conditions in the United States or internationally, as well as those
risks more fully discussed in the section entitled “Risk Factors” in
Rocket’s Annual Report on Form 10-K for the year ended December 31,
2018. Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of the
date made, and Rocket undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.

Contacts

Claudine Prowse, Ph.D.
SVP Corporate Development and IRO
Rocket
Pharmaceuticals, Inc.
The Empire State Building, Suite 7530
New
York, NY 10118
[email protected]

NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (Nasdaq:RCKT) (“Rocket”), a leading
U.S.-based multi-platform gene therapy company, today announces the
closing of its previously announced underwritten public offering of
5,175,000 shares of its common stock, which includes the full exercise
of the underwriters’ option to purchase 675,000 additional shares of its
common stock, at a public offering price of $17.50 per share. The gross
proceeds to Rocket from the offering are expected to be approximately
$90.6 million, before deducting the underwriting discounts and
commissions and other offering expenses.

Rocket intends to use the net proceeds from this offering to further
fund the development of its pipeline of gene therapies for rare
diseases, to accelerate the buildout of in-house manufacturing
capabilities, and for general corporate purposes.

SVB Leerink, Evercore ISI and William Blair acted as joint-bookrunning
managers for the offering. Oppenheimer & Co. acted as lead manager for
the offering.

The public offering was made by Rocket pursuant to an effective shelf
registration statement on Form S-3 that was previously filed with the
U.S. Securities and Exchange Commission (the “SEC”) and declared
effective by the SEC. A final prospectus supplement relating to and
describing the terms of this offering was filed with the SEC on April
17, 2019. Copies of the final prospectus supplement and the accompanying
prospectus relating to these securities may be obtained from SVB Leerink
LLC, Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email [email protected];
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd
Street, 36th Floor, New York, NY 10055, by telephone at (888) 474-0200,
or by email at [email protected];
and William Blair & Company, L.L.C., Attention: Prospectus Department,
150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800)
621-0687, or by email at [email protected].
You may also obtain these documents free of charge by visiting the SEC’s
website at www.sec.gov.

This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.

Forward-looking Statements

Various statements in this release concerning Rocket’s future
expectations, plans and prospects, including without limitation, the
anticipated use of the net proceeds of the offerings, may constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995
and other federal securities laws and are subject to substantial risks,
uncertainties and assumptions. You should not place reliance on these
forward-looking statements, which often include words such as
“anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“seek,” “should,” “suggest,” “target,” “will,” “will give,” “would,” or
similar terms, variations of such terms or the negative of those terms.
Although Rocket believes that the expectations reflected in the
forward-looking statements are reasonable, Rocket cannot guarantee such
outcomes. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including, without limitation, changes as a result of market
conditions or for other reasons, the risk that the offerings will not be
consummated, and the impact of general economic, industrial or political
conditions in the United States or internationally, as well as those
risks more fully discussed in the section entitled “Risk Factors” in
Rocket’s Annual Report on Form 10-K for the year ended December 31,
2018. Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of the
date made, and Rocket undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.

Contacts

Claudine Prowse, Ph.D.
SVP Corporate Development and IRO
Rocket
Pharmaceuticals, Inc.
The Empire State Building, Suite 7530
New
York, NY 10118
[email protected]

leverton

Content is the most important part of having quality links to your website. With Area-Info.net, we provide a quality location to share your story and include links to your website to help you grow. If you would like to learn more, visit this page to see how you can use Area-Info.net to rank higher and quicker in search engines. Contact me directly at [email protected] with any questions, or to schedule speaking engagements.

You May Also Like